HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NAD Fed Up With ‘Confidentiality’ Cop-Outs; Are Advertisers ‘Hiding The Ball’?

This article was originally published in The Rose Sheet

Executive Summary

The National Advertising Division is weary of companies claiming confidentiality in its dispute resolution forum without adequately detailed cause or earnest efforts to meet the option’s requirements. A panel at the group’s annual meeting discussed the issue and steps advertisers should take to protect their competitive interests without compromising themselves or the self-regulatory system.

You may also be interested in...



National Advertising Division’s Updated Procedures Allow Reopening Of Old Cases

Marketers now can petition NAD to reopen cases if they have new studies or other data supporting ad claims that were shot down by the watchdog group previously, though the bar for re-review is high, says NAD Director Laura Brett.

NAD: Sea & Ski Sunscreens May Go ‘Beyond UV,’ But Not To Infrared Zone

Cross Brands Manufacturing’s stingily hand-picked in vitro test results for Sea & Ski sunscreens do not demonstrate a clear, consumer-relevant infrared protection capability, let alone show that IR defense translates to meaningful skin-health benefits, according to the National Advertising Division’s Sept. 7 decision.

NAD Has ‘High Hopes’ Firms Will Cooperate On Schedules To Accelerate Reviews

The National Advertising Division changes its review process to allow opposing companies greater control over scheduling and resolving their disputes. The changes, recommended by ABA committees, also impose fees on both firms in appeals and allow more time for compliance with decisions.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121854

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel